The US Supreme Court will hear generic drug maker Hikma Pharmaceuticals USA Inc.'s challenge of an appeals court holding that ...
The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...
MedPage Today on MSN
FDA says to drop suicide warning from GLP-1 drug labels
Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...
The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...
The FDA is weighing a change that could make warning labels on dietary supplements appear less often on packaging.
A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.
WASHINGTON — The Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to treat attention-deficit hyperactivity disorder to include warnings ...
The FDA proposes front-of-package "Nutrition Info boxes" to highlight saturated fat, sodium, and added sugars. The initiative aims to combat chronic diseases and promote healthier food choices. Large ...
The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback